Genxone Spolka Akcyjna Logo

Genxone Spolka Akcyjna

GX1 | WAR

Overview

Corporate Details

ISIN(s):
PLGENXN00013
LEI:
25940043REFNZY18T558
Country:
Poland
Address:
SUCHY LAS ZŁOTNIKI, KOBALTOWA 6, 62-002 SUCHY LAS
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Genxone S.A. is a biotechnology company specializing in Next-Generation Sequencing (NGS) and medical diagnostics. The company provides nucleic acid (DNA and RNA) sequencing services based on innovative nanopore technology from Oxford Nanopore Technologies. As a pioneer in the field, it was the first laboratory in Poland and among the first globally to implement this technology for commercial use in science, business, and medicine. In addition to its sequencing services, Genxone develops and commercializes its own diagnostic products, including the NANOBIOME gut microbiome test.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Genxone Spolka Akcyjna. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2024-03-08 14:25
Regulatory News Service
Podpisanie umowy warunkowej o istotnym znaczeniu - Content (PL)
Polish 1.2 KB
2024-03-06 16:41
Regulatory News Service
Informacja o wyborze najkorzystniejszej oferty - Content (PL)
Polish 1.8 KB
2023-11-16 15:32
Related Party Transaction
Podpisanie umowy warunkowej o istotnym znaczeniu - Content (PL)
Polish 1.1 KB
2023-11-14 14:32
Legal Proceedings Report
Informacja o wyborze najkorzystniejszej oferty - Content (PL)
Polish 1.7 KB
2023-10-23 16:34
Regulatory News Service
Aktualizacja informacji na temat umowy warunkowej o istotnym znaczeniu - Conten…
Polish 948 bytes
2023-07-20 15:09
M&A Activity
Zawarcie istotnej umowy - Content (PL)
Polish 1.0 KB
2023-06-19 15:31
Declaration of Voting Results & Voting Rights Announcements
Lista akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zg…
Polish 470 bytes
2023-05-22 15:37
Business and Financial Review
Sprawozdanie RN genXone za 2022 rok
Polish 991.6 KB
2023-05-22 15:37
Pre-Annual General Meeting Information
Projekty uchwał WZA genXone SA
Polish 284.6 KB
2023-05-22 15:37
Pre-Annual General Meeting Information
Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia Spółki genXone SA
Polish 291.5 KB
2023-05-22 15:37
Pre-Annual General Meeting Information
Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia Spółki genXone S.A. na d…
Polish 6.6 KB
2023-05-09 15:57
Related Party Transaction
Podpisanie umowy warunkowej o istotnym znaczeniu - Content (PL)
Polish 857 bytes
2023-05-05 16:54
Related Party Transaction
Informacja o wyborze najkorzystniejszej oferty - Content (PL)
Polish 1.5 KB
2023-04-26 17:03
Regulatory News Service
Aktualizacja informacji na temat prac badawczych w ramach projektu NANOBIOME - …
Polish 1.7 KB
2023-03-21 08:05
Director's Dealing
Zawiadomienia_o_transakcjach_osoby_zobowiazanej_Jakub_Swadzba_20230320.pdf
Polish 9.7 KB

Automate Your Workflow. Get a real-time feed of all Genxone Spolka Akcyjna filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Genxone Spolka Akcyjna via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN